Hanall Biopharma한올바이오파마
009420 · KOSPI · ₩009420 · 한올바이오파마
₩37,800▼ ₩700 (1.82%)End-of-day · Oct 29, 2026 · End-of-day prices.
Margins
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Gross margin | 52.8% | 52.1% | 52.8% | 55.7% | 56.3% | 59.4% |
| Operating margin | 2.9% | −0.6% | 0.2% | 1.6% | 1.4% | 9.9% |
| Net margin | −15.3% | −3.6% | −1.3% | 2.6% | 0.2% | 8.8% |
Growth (year on year)
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue growth | +4.8% | +11.7% | +3.0% | +22.7% | +8.3% | — |
| Operating income growth | +620.8% | −497.4% | −89.6% | +46.9% | −85.1% | — |
| Net income growth | −348.0% | −208.0% | −151.4% | +1,295.2% | −97.2% | — |
Returns
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Return on equity | −15.4% | −3.4% | −1.0% | 2.0% | 0.2% | 5.4% |
| Return on assets | −10.9% | −2.5% | −0.8% | 1.5% | 0.1% | 4.5% |
Leverage and liquidity
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Liabilities to equity | 48.8% | 39.3% | 26.5% | 28.7% | 26.9% | 21.4% |
| Net debt to equity | 8.6% | 3.7% | — | — | — | — |
| Current ratio | 149.4% | 191.0% | 245.8% | 301.7% | 391.8% | 537.1% |
Calculated from filed financial statements. TTM = trailing 12 months.
Also known as: Hanall Biopharma / 한올바이오파마 / 009420 / KRX:009420
Source: KRX statistical information